| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... Leukemia 36 (7), 1703-1719, 2022 | 1736 | 2022 |
| NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines DA Pollyea, D Bixby, A Perl, VR Bhatt, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 19 (1), 16-27, 2021 | 227 | 2021 |
| Prognostic significance of tumor infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemotherapy R Nejati, JB Goldstein, DM Halperin, H Wang, N Hejazi, A Rashid, ... Pancreas 46 (9), 1180, 2017 | 58 | 2017 |
| Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas J Svoboda, SM Bair, DJ Landsburg, SD Nasta, SJ Nagle, SK Barta, ... Haematologica 106 (6), 1705, 2021 | 50 | 2021 |
| Neuro-immune-endocrine functions of the skin: an overview R Nejati, D Kovacic, A Slominski Expert review of dermatology 8 (6), 581-583, 2013 | 48 | 2013 |
| Genetic variation of the cutaneous HPA axis: an analysis of UVB-induced differential responses C Skobowiat, R Nejati, L Lu, RW Williams, AT Slominski Gene 530 (1), 1-7, 2013 | 38 | 2013 |
| Menstrual irregularities and related plasma hormone levels in multiple sclerosis patients treated with beta interferone SM Nabavi, SA Koupai, MR Nejati, E Garshasbi, MR Jalali Acta Medica Iranica, 36-41, 2010 | 36 | 2010 |
| Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication P Lu, S Wang, CA Franzen, G Venkataraman, R McClure, L Li, W Wu, ... Blood cancer journal 11 (2), 1-14, 2021 | 33 | 2021 |
| Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology DA Pollyea, JK Altman, R Assi, D Bixby, AT Fathi, JM Foran, I Gojo, ... Journal of the National Comprehensive Cancer Network 21 (5), 503-513, 2023 | 29 | 2023 |
| IGH/MYC translocation associates with BRCA2 deficiency and synthetic lethality to PARP1 inhibitors S Maifrede, K Martin, P Podszywalow-Bartnicka, K Sullivan-Reed, ... Molecular Cancer Research 15 (8), 967-972, 2017 | 27 | 2017 |
| Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome Q Zhang, EJ Orlando, HY Wang, AM Bogusz, X Liu, SF Lacey, ... blood 136 (17), 1980-1983, 2020 | 23 | 2020 |
| PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm PP Aung, N Sukswai, R Nejati, S Loghavi, W Chen, CA Torres-Cabala, ... Cancers 11 (5), 695, 2019 | 22 | 2019 |
| TGFβR-SMAD3 signaling induces resistance to PARP inhibitors in the bone marrow microenvironment BV Le, P Podszywalow-Bartnicka, S Maifrede, K Sullivan-Reed, ... Cell reports 33 (1), 108221, 2020 | 20 | 2020 |
| Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma Z Song, W Wei, W Xiao, ED Al-Saleem, R Nejati, L Chen, J Yin, J Fabrizio, ... Proceedings of the National Academy of Sciences 117 (46), 28980-28991, 2020 | 11 | 2020 |
| Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines DA Pollyea, D Bixby, A Perl, VR Bhatt, JK Altman, FR Appelbaum, ... JNCCN Journal of the National Comprehensive Cancer Network 19 (1), 16-27, 2021 | 10 | 2021 |
| Resection and abdominal wall reconstruction of a desmoid tumor with endometrioma features J Majors, NF Stoikes, R Nejati, JL Deneve Case reports in surgery 2016, 2016 | 9 | 2016 |
| Commentary on the practical guide for the study of sebaceous glands R Nejati, C Skobowiat, AT Slominski Experimental dermatology 22 (10), 629-630, 2013 | 8 | 2013 |
| DNA polymerase θ protects leukemia cells from metabolically induced DNA damage U Vekariya, M Toma, M Nieborowska-Skorska, BV Le, MC Caron, ... Blood, The Journal of the American Society of Hematology 141 (19), 2372-2389, 2023 | 6 | 2023 |
| Induction of transcriptional inhibitor HES1 and the related repression of tumor-suppressor TXNIP are important components of cell-transformation program imposed by oncogenic … Q Zhang, HY Wang, A Nayak, S Nunez-Cruz, A Slupianek, X Liu, ... The American Journal of Pathology 192 (8), 1186-1198, 2022 | 5 | 2022 |
| Lymphocyte exhaustion in AML patients and impacts of HMA/venetoclax or intensive chemotherapy on their biology D Zhigarev, A Varshavsky, AW MacFarlane IV, P Jayaguru, L Barreyro, ... Cancers 14 (14), 3352, 2022 | 5 | 2022 |
